{"nctId":"NCT04957212","briefTitle":"Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer","startDateStruct":{"date":"2018-08-11","type":"ACTUAL"},"conditions":["HER2-positive Breast Cancer"],"count":214,"armGroups":[{"label":"TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)","type":"EXPERIMENTAL","interventionNames":["Drug: Trastuzumab","Drug: Pertuzumab","Drug: Carboplatin","Drug: Docetaxel"]},{"label":"TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Trastuzumab","Drug: Pertuzumab","Drug: Carboplatin","Drug: Docetaxel"]}],"interventions":[{"name":"Trastuzumab","otherNames":[]},{"name":"Pertuzumab","otherNames":[]},{"name":"Carboplatin","otherNames":[]},{"name":"Docetaxel","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female patients aged 18-70 years.\n* Diagnosed with locally advanced (T2-3, N2-3, M0 or T4a-c, any N, M0), inflammatory (T4d, any N, M0) or operable (T2-3, N0-1, M0), invasive breast cancer.\n* Primary tumor \\> 2 cm in diameter.\n* HER2 positive breast cancer confirmed (Tumors must be IHC 3+ or FISH/CISH + for IHC 2+ tumors).\n* Baseline LVEF ≥ 55% measured by echocardiography.\n* Performance status ECOG ≤ 1\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV) or bilateral breast cancer.\n* Previous anticancer therapy or radiotherapy for any malignancy.\n* Other malignancy, except for carcinoma in situ of the cervix or basal cell carcinoma.\n* Received any investigational treatment within 4 weeks of study start.\n* At least 4 weeks since major surgery.\n* Uncontrolled hypertension (systolic \\> 150 and/or diastolic \\> 100), unstable angina, CHF of any NYHA classification, serious cardiac arrhythmia requiring treatment, history of myocardial infarction within 6 months of enrollment.\n* Hematological, biochemical and organ dysfunction:\n\n  1. Inadequate bone marrow function: Absolute Neutrophil Count (ANC) \\< 1500 cells/ µL, Platelet count \\< 100,000 cells/ µL and Hb \\< 9 g/dL).\n  2. Impaired liver function: serum \\[total\\] bilirubin \\> 1.25 x ULN, AST/ALT \\> 1. 5 x ULN with ALP \\> 2.5 x ULN\n  3. Inadequate renal function: serum creatinine \\> 1.5 x ULN.\n* Dyspnea at rest or other diseases which require continuous oxygen therapy.\n* Severe uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic, etc).\n* Current chronic daily treatment with corticosteroids (dose of ≥10 mg Oral prednisolone, or equivalent \\[excluding inhaled steroids\\])\n* Subjects with known infection with HIV, HBV, and HCV.\n* Known hypersensitivity to any of the study drugs or excipients.\n* Pregnant and/or lactating women or subjects with reproductive potential not willing to use effective methods of contraception.\n* Subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol (e.g.: physical, psychological and mental problems)","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Breast Pathological Complete Response (bpCR)","description":"bpCR defined as the absence of invasive neoplastic cells in the breast at microscopic examination of the primary tumor at surgery following primary systemic therapy (ypT0/is)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Pathological Complete Response (tpCR)","description":"tpCR defined as no invasive tumor residues in the breast and lymph nodes (ypT0/is ypN0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"ORR defined as the proportion of patients who achieved a complete or partial response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"61","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"29","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Breast-conserving Surgery (BCS)","description":"Rate of BCS for patients for whom mastectomy was planned before treatment (T2-3)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Assessment Including Treatment Related Adverse Events","description":"Safety assessment, including the incidence of all reported AEs and abnormal laboratory results was done. All AEs were classified based on the Medical Dictionary for Regulatory Activities (MedDRA Desktop Browser 4.0 Beta) terms as System Organ Class (SOC) and Preferred Term (PT). All the reported events were graded according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). Moreover, seriousness of AEs was assessed according to International Council for Harmonization (ICH-E2B) guidelines. The causality relation was assessed based on the World Health Organization (WHO) criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"107","spread":null}]}]}]},{"type":"SECONDARY","title":"Abnormal Laboratory Data","description":"Laboratory data including CBC diff have been assessed. All abnormal values were recorded as adverse event.","classes":[]},{"type":"SECONDARY","title":"Decrease in Left Ventricular Ejection Fraction (LVEF)","description":"LVEF decrease was measured by echocardiography. All cases with a decrease more than 10% from baseline which meet \\<50%, will be recorded as adverse events.","classes":[]},{"type":"SECONDARY","title":"Incidence of Symptomatic Left Ventricular Systolic Dysfunction (LVSD)","description":"In this study, LVSD was evaluated by measuring the decrease in LVEF (outcome measure 5) and assessing the clinical symptoms of the study participants based on physician opinion.","classes":[]},{"type":"SECONDARY","title":"Immunogenicity","description":"The enzyme-linked immunosorbent assay (ELISA) method was used for the assessment of anti-drug antibodies (ADAs).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":107},"commonTop":["Anaemia","Thrombocytopenia","Nausea","Diarrhoea","Leukopenia"]}}}